
Insulet Corporation PODD
$ 230.37
2.54%
Quarterly report 2025-Q3
added 03-14-2026
Insulet Corporation Gross Profit 2011-2026 | PODD
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Insulet Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.94 B | 1.45 B | 1.16 B | 806 M | 752 M | 582 M | 480 M | 110 M | 277 M | 211 M | 148 M | 143 M | 112 M | 92.3 M | 66.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.94 B | 66.7 M | 555 M |
Quarterly Gross Profit Insulet Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 510 M | 452 M | 409 M | - | 377 M | 331 M | 307 M | - | 293 M | 265 M | 240 M | - | 188 M | 190 M | 210 M | - | 189 M | 183 M | 168 M | - | 152 M | 142 M | 127 M | 134 M | 123 M | 116 M | 107 M | 110 M | 102 M | 82.1 M | 75.8 M | 79.5 M | 73.6 M | 64.6 M | 59.4 M | 60.9 M | 55.6 M | 50.5 M | 44.1 M | 42 M | 31.6 M | 30.5 M | 29.2 M | 33.1 M | 33.7 M | 31.8 M | 28.4 M | 33 M | 27.4 M | 26.8 M | 25.2 M | 25.3 M | 24.4 M | 22.3 M | 20.3 M | 20.1 M | 18.6 M | 14.5 M | 13.5 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 510 M | 13.5 M | 122 M |
Gross Profit of other stocks in the Medical devices industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aethlon Medical
AEMD
|
1.36 M | $ 2.2 | 4.29 % | $ 3.43 M | ||
|
AdaptHealth Corp.
AHCO
|
89.3 M | $ 10.55 | 1.2 % | $ 1.43 B | ||
|
Allied Healthcare Products
AHPI
|
443 K | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
67.9 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
-3.14 M | - | -26.83 % | $ 2.62 M | ||
|
Butterfly Network
BFLY
|
48.8 M | $ 4.21 | 7.54 % | $ 891 M | ||
|
Alphatec Holdings
ATEC
|
532 M | $ 12.97 | 2.94 % | $ 1.95 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
584 K | - | -5.86 % | $ 30.6 M | ||
|
Aziyo Biologics
AZYO
|
6.6 M | - | 1.37 % | $ 20.5 M | ||
|
Cognyte Software Ltd.
CGNT
|
247 M | $ 8.37 | -0.12 % | $ 601 M | ||
|
Avinger
AVGR
|
2 M | - | -20.74 % | $ 369 K | ||
|
BIOLASE
BIOL
|
16.7 M | - | -13.19 % | $ 166 K | ||
|
Boston Scientific Corporation
BSX
|
13.9 B | $ 71.18 | 1.99 % | $ 105 B | ||
|
CONMED Corporation
CNMD
|
750 M | $ 37.16 | -0.64 % | $ 1.15 B | ||
|
Conformis
CFMS
|
23.2 M | - | - | $ 16.4 M | ||
|
Cytosorbents Corporation
CTSO
|
25.1 M | $ 0.69 | 6.15 % | $ 37.6 M | ||
|
EDAP TMS S.A.
EDAP
|
26.6 M | $ 4.05 | 2.27 % | $ 151 M | ||
|
Apollo Endosurgery
APEN
|
42.4 M | - | - | $ 475 M | ||
|
Cutera
CUTR
|
-12.7 M | - | -10.19 % | $ 1.99 M | ||
|
Establishment Labs Holdings
ESTA
|
146 M | $ 65.07 | 2.5 % | $ 1.93 B | ||
|
CryoLife, Inc.
CRY
|
168 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
6.01 M | - | 14.99 % | $ 929 K | ||
|
ClearPoint Neuro
CLPT
|
19.1 M | $ 11.17 | 1.27 % | $ 302 M | ||
|
Axonics Modulation Technologies
AXNX
|
198 M | - | - | $ 3.31 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
28.7 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
43.7 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
1.99 M | - | - | $ 111 M | ||
|
FONAR Corporation
FONR
|
42.4 M | $ 18.43 | 0.05 % | $ 121 M | ||
|
Helius Medical Technologies
HSDT
|
61 K | $ 2.21 | 0.91 % | $ 1.34 M | ||
|
GBS
GBS
|
1.25 M | - | -0.57 % | $ 7.12 M | ||
|
InMode Ltd.
INMD
|
291 M | $ 13.59 | 1.19 % | $ 878 M | ||
|
IRIDEX Corporation
IRIX
|
21.8 M | $ 1.34 | 0.75 % | $ 21.6 M | ||
|
Intersect ENT, Inc.
XENT
|
50.2 M | - | - | $ 955 M | ||
|
Abbott Laboratories
ABT
|
18.7 B | $ 111.55 | 1.44 % | $ 194 B | ||
|
Delcath Systems
DCTH
|
73.4 M | $ 9.84 | 0.31 % | $ 352 M | ||
|
Bio-Rad Laboratories
BIO
|
342 M | $ 269.01 | 3.04 % | $ 7.59 B | ||
|
LivaNova PLC
LIVN
|
940 M | $ 62.67 | 2.01 % | $ 3.42 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
953 M | $ 9.18 | 1.89 % | $ 707 M | ||
|
AxoGen
AXGN
|
167 M | $ 33.08 | 0.72 % | $ 1.52 B | ||
|
Align Technology
ALGN
|
2.8 B | $ 178.3 | 5.22 % | $ 13.4 B | ||
|
MiMedx Group
MDXG
|
346 M | $ 4.38 | -0.79 % | $ 647 M | ||
|
Bruker Corporation
BRKR
|
1.65 B | $ 33.83 | 3.27 % | $ 5.04 K | ||
|
BioSig Technologies
BSGM
|
229 K | - | 37.08 % | $ 85.7 M | ||
|
Apyx Medical Corporation
APYX
|
33 M | $ 3.76 | 2.45 % | $ 155 M | ||
|
OrthoPediatrics Corp.
KIDS
|
173 M | $ 17.27 | 0.94 % | $ 405 M | ||
|
Integer Holdings Corporation
ITGR
|
500 M | $ 86.5 | 2.89 % | $ 3 B |